Treprostinil palmitil (TP) inhalation powder (TPIP), an investigational formulation of the treprostinil prodrug TP, was designed to provide prolonged pulmonary vasodilation with once-daily administration. 

This study explored attitudes towards exercise, recollections of physical activity advice received, and the dimensions that influence physical activity (PA) engagement in individuals diagnosed with pulmonary hypertension. Virtual semi-structured interviews (n = 21) were conducted with those diagnosed with pulmonary hypertension. 

Group discussion session at Genetics-inspired Therapeutics for PH

Presented at Genetics-inspired Therapeutics for PH by Chris Rhodes, Imperial College London

Presented at Genetics-inspired Therapeutics for PH by Rachel Gurrell, Apollo Therapeutics

Presented at Genetics-inspired Therapeutics for PH by Patrick Andre, Diagonal Therapeutics

Presented at Genetics-inspired Therapeutics for PH by Alex Rothman, The University of Sheffield and Ana-Maria Tanase, Novartis

Presented at Genetics-inspired Therapeutics for PH by Kevin Hart, Pfizer

Presented at Genetics-inspired Therapeutics for PH by Khodr Tello, Justus-Liebig-Universität Gießen

The SPHInX study is the first-ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH).